Basel - On 12 November, Lonza will host a free 60-minute webinar during which Nephron Pharmaceuticals will explain its decision to take a paperless approach to batch record management.
Nephron will also discuss how its close relationship with Lonza allowed for a rapid implementation of Lonza's MODA-ESTM Electronic Batch Record (EBR) Platform in just nine months, leading to increased operational efficiency and expanded product lines.
Recording batch data is an essential part of the pharmaceutical manufacturing process. However, the wealth of information generated by each batch is traditionally collected using paper-based workflows, which are inherently resource intensive, time consuming and can negatively impact the time-to-market for new therapeutics. As such, pharmaceutical manufacturers are increasingly turning to paperless EBR solutions to eliminate these challenges.
In the webinar titled 'Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success,' Bryan Beck, Vice President for Automation and Information Technology at Nephron Pharmaceuticals, will discuss the following topics
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.
Dr. Kristin Koehler
Tel: +41 61 316 8782
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
(C) 2019 Electronic News Publishing, source ENP Newswire